Molecular Diagnostic Approach to Liver Tissue as an Ancillary Tool for Liver Histopathology

ABSTRACT

Diagnostic liver histopathology is currently based on the microscopic assessment of morphological and immunohistochemical features in a biopsy. In other fields of diagnostic pathology, it has been shown that the diagnostic process can be improved by the incorporation of ancillary molecular techniques and this will most likely also occur in liver pathology in the future. This article gives an overview of several liver diseases for which the diagnosis could be improved by the addition of a molecular technique to the classical histopathologic working method. For each of these diseases, the most promising molecular techniques are discussed. It is very likely that ancillary molecular techniques will be applied in routine practice to improve diagnosis and prognostication of liver tumors in the foreseeable future.

KEYWORDS

Molecular diagnosis - liver diagnosis - microarray - real-time reverse-transcriptase PCR

REFERENCES

• 1 McSween R NM, Burt A D, Portmann B, Ishak K G. Pathology of the Liver. 4th ed. London; Churchill Livingstone 2002
• 2 Crocker J. Demystified: molecular pathology in oncology.  Mol Pathol. 2002;  55 337-347
• 3 Pietrangelo A. Molecular insights into the pathogenesis of hereditary haemochromatosis.  Gut. 2006;  55 564-568
• 4 Jansen P LM, Sturm E. Genetic cholestasis, causes and consequences for hepatobiliary transport.  Liver Int. 2003;  23 315-322
• 5 Ryder S D. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study.  Gut. 2004;  53 451-455
• 6 Rubbia-Brandt L, Fabris P, Paganin S et al.. Steatosis affects chronic hepatitis C progression in a genotype specific way.  Gut. 2004;  53 406-412
• 7 Camps J, Crisostomo S, Garciagranero M et al.. Prediction of the response of chronic hepatitis C to interferon alfa: a statistical analysis of pretreatment variables.  Gut. 1993;  34 1714-1717
• 8 Massard J, Ratziu V, Thabut D et al.. Natural history and predictors of disease severity in chronic hepatitis C.  J Hepatol. 2006;  44 S19-S24
• 9 Wilson L E, Torbenson M, Astemborski J et al.. Progression of liver fibrosis among injection drug users with chronic hepatitis C.  Hepatology. 2006;  43 788-795
• 10 Jensen D M, Morgan T R, Marcellin P et al.. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy.  Hepatology. 2006;  43 954-960
• 11 Feld J J, Liang T J. Hepatitis C: identifying patients with progressive liver injury.  Hepatology. 2006;  43 S194-S206
• 12 Smith M W, Walters K A, Korth M J et al.. Gene expression patterns that correlate with hepatitis C and early progression to fibrosis in liver transplant recipients.  Gastroenterology. 2006;  130 179-187
• 13 Chen L, Borozan I, Feld J et al.. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection.  Gastroenterology. 2005;  128 1437-1444
• 14 Hayashida K, Daiba A, Sakai A et al.. Pretreatment prediction of interferon-alfa efficacy in chronic hepatitis C patients.  Clin Gastroenterol Hepatol. 2005;  3 1253-1259
• 15 Yeung E, Chung R T. Microarrays and prediction of interferon response in chronic hepatitis C: not yet ready for prime time.  Clin Gastroenterol Hepatol. 2005;  3 1192-1194
• 16 Kim I J, Kang H C, Park J G. Evaluation of microarray analysis for predicting treatment responsiveness in patients with chronic hepatitis C viral infection.  Gastroenterology. 2005;  129 1803
• 17 Grassi G, Pozzato G, Moretti M, Giacca M. Quantitative analysis of hepatitis C virus RNA in liver biopsies by competitive reverse transcription and polymerase chain reaction.  J Hepatol. 1995;  23 403-411
• 18 Gervais A, Martinot M, Boyer N et al.. Quantitation of hepatic hepatitis C virus RNA in patients with chronic hepatitis C: relationship with severity of disease, viral genotype and response to treatment.  J Hepatol. 2001;  35 399-405
• 19 McHutchison . Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin.  Hepatology. 2002;  35 688-693
• 20 Lee W M. Acute liver failure in the United States.  Semin Liver Dis. 2003;  23 217-226
• 21 Nunez-Martinez O, De la Cruz G, De Diego A et al.. Liver transplantation for fulminant and subfulminant hepatic failure.  Transplant Proc. 2003;  35 1855-1856
• 22 Tessier G, Villeneuve E, Villeneuve J P. Etiology and outcome of acute liver failure: experience from a liver transplantation centre in Montreal.  Can J Gastroenterol. 2002;  16 672-676
• 23 Huang Q, Jin X, Gaillard E T et al.. Gene expression profiling reveals multiple toxicity endpoints induced by hepatotoxicants.  Mutat Res. 2004;  549 147-167
• 24 Ulrich R G, Rockett J C, Gibson G G, Pettit S D. Overview of an interlaboratory collaboration on evaluating the effects of model hepatotoxicants on hepatic gene expression.  Environ Health Perspect. 2004;  112 423-427
• 25 Waring J F, Ciurlionis R, Jolly R A et al.. Microarray analysis of hepatotoxins in vitro reveals a correlation between gene expression profiles and mechanisms of toxicity.  Toxicol Lett. 2001;  120 359-368
• 26 Inkinen K, Lahesmaa R, Brandt A et al.. DNA microarray-based gene expression profiles of cytomegalovirus infection and acute rejection in liver transplants.  Transplant Proc. 2005;  37 1227-1229
• 27 Krukemeyer M G, Moeller J, Morawietz L et al.. Description of B lymphocytes and plasma cells, complement, and chemokines/receptors in acute liver allograft rejection.  Transplantation. 2004;  78 65-70
• 28 Cookson S, Doherty D G, Todryk S et al.. Hepatic expression of IL-15 mRNA is associated with liver graft acceptance.  Transpl Immunol. 2003;  11 39-48
• 29 Flach R, Speidel N, Flohe S et al.. Analysis of intragraft cytokine expression during early reperfusion after liver transplantation using semi-quantitative RT-PCR.  Cytokine. 1998;  10 445-451
• 30 Hytiroglou P, Theise N D. Differential diagnosis of hepatocellular nodular lesions.  Semin Diagn Pathol. 1998;  15 285-299
• 31 Vander Borght S, Libbrecht L, Blokzijl H et al.. Diagnostic and pathogenetic implications of the expression of hepatic transporters in focal lesions occurring in normal liver.  J Pathol. 2005;  207 471-482
• 32 Makhlouf H R, Abdul-Al H M, Goodman Z D. Diagnosis of focal nodular hyperplasia of the liver by needle biopsy.  Hum Pathol. 2005;  36 1210-1216
• 33 Fabre A, Audet P, Vilgrain V et al.. Histologic scoring of liver biopsy in focal nodular hyperplasia with atypical presentation.  Hepatology. 2002;  35 414-420
• 34 Chen Z ME, Crone K G, Watson M A et al.. Identification of a unique gene expression signature that differentiates hepatocellular adenoma from well-differentiated hepatocellular carcinoma.  Am J Surg Pathol. 2005;  29 1600-1608
• 35 Bioulac-Sage P, Rebouissou S, Cunha A S et al.. Clinical, morphologic, and molecular features defining so-called telangiectatic focal nodular hyperplasias of the liver.  Gastroenterology. 2005;  128 1211-1218
• 36 Paradis V, Benzekri A, Dargere D et al.. Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma.  Gastroenterology. 2004;  126 1323-1329
• 37 Paradis V, Bieche I, Dargere D et al.. A quantitative gene expression study suggests a role for angiopoietins in focal nodular hyperplasia.  Gastroenterology. 2003;  124 651-659
• 38 Zucman-Rossi J, Jeannot E, Van Nhieu J T et al.. Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC.  Hepatology. 2006;  43 515-524
• 39 Wilkens L, Bredt M, Flemming P et al.. Diagnostic impact of fluorescence in situ hybridization in the differentiation of hepatocellular adenoma and well-differentiated hepatocellular carcinoma.  J Mol Diagn. 2001;  3 68-73
• 40 Wilkens L, Bredt M, Flemming P et al.. Differentiation of liver cell adenomas from well-differentiated hepatocellular carcinomas by comparative genomic hybridization.  J Pathol. 2001;  193 476-482
• 41 Matsui O. Detection and characterization of hepatocellular carcinoma by imaging.  Clin Gastroenterol Hepatol. 2005;  3 S136-S140
• 42 Bolondi L, Gaiani S, Celli N et al.. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma.  Hepatology. 2005;  42 27-34
• 43 Krinsky G. Imaging of dysplastic nodules and small hepatocellular carcinomas: experience with explanted livers.  Intervirology. 2004;  47 191-198
• 44 Bruix J, Sherman M, Llovet J M et al.. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference.  J Hepatol. 2001;  35 421-430
• 45 Libbrecht L, Desmet V, Roskams T. Preneoplastic lesions in human hepatocarcinogenesis.  Liver Int. 2005;  25 16-27
• 46 Libbrecht L, Severi T, Cassiman D et al.. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules and focal nodular hyperplasia-like nodules.  Am J Surg Pathol. , In press
• 47 Capurro M, Wanless I R, Sherman M et al.. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma.  Gastroenterology. 2003;  125 89-97
• 48 Chang H Y, Nuyten D SA, Sneddon J B et al.. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival.  Proc Natl Acad Sci USA. 2005;  102 3738-3743
• 49 Di Bisceglie A M. Pretransplant treatments for hepatocellular carcinoma: do they improve outcomes?.  Liver Transpl. 2005;  11 S10-S13
• 50 Befeler A S, Hayashi P H, Di Bisceglie A M. Liver transplantation for hepatocellular carcinoma.  Gastroenterology. 2005;  128 1752-1764
• 51 Wiesner R H. Patient selection in an era of donor liver shortage: current US policy.  Nat Clin Pract Gastroenterol Hepatol. 2005;  2 24-30
• 52 Cillo U, Vitale A, Bassanello M et al.. Liver transplantation for the treatment of moderately or well-differentiated hepatocellular carcinoma.  Ann Surg. 2004;  239 150-159
• 53 Thorgeirsson S S, Grisham J W. Molecular pathogenesis of human hepatocellular carcinoma.  Nat Genet. 2002;  31 339-346
• 54 Kurokawa Y, Matoba R, Takemasa I et al.. Molecular-based prediction of early recurrence in hepatocellular carcinoma.  J Hepatol. 2004;  41 284-291
• 55 Iizuka N, Oka M, Yamada-Okabe H et al.. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection.  Lancet. 2003;  361 923-929
• 56 Ye Q H, Qin L X, Forgues M et al.. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning.  Nat Med. 2003;  9 416-423
• 57 Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy.  Lancet. 2005;  365 488-492
• 58 Ein-Dor L, Zuk O, Domany E. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer.  Proc Natl Acad Sci USA. 2006;  103 5923-5928
• 59 Lee J S, Chu I S, Heo J et al.. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling.  Hepatology. 2004;  40 667-676
• 60 Hu Z, Fan C, Oh D S et al.. The molecular portraits of breast tumors are conserved across microarray platforms.  BMC Genomics. 2006;  7 96
• 61 Lee J S, Heo J, Libbrecht L et al.. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells.  Nat Med. 2006;  12 410-416
• 62 Marsh J W, Finkelstein S D, Schwartz M E et al.. Advancing the diagnosis and treatment of hepatocellular carcinoma.  Liver Transpl. 2005;  11 469-472
• 63 Libbrecht L, Lee Y S, Durnez A et al.. Microvascular invasion in hepatocellular carcinoma is correlated with differentiation grade, tumor diameter and with unsupervised classification based on gene expression patterns. Abstract book of the EASL/AASLD/JSH monothematic conference on hepatocellular carcinoma 2005: 10
• 64 Marsh J W, Finkelstein S D, Demetris A J et al.. Genotyping of hepatocellular carcinoma in liver transplant recipients adds predictive power for determining recurrence-free survival.  Liver Transpl. 2003;  9 664-671
• 65 Sherman M. Screening for hepatocellular carcinoma.  Best Pract Res Clin Gastroenterol. 2005;  19 101-118
• 66 Bruix J, Sherman M. Management of hepatocellular carcinoma.  Hepatology. 2005;  42 1208-1236
• 67 Fattovich G, Llovet J M. Risk factors for hepatocellular carcinoma in HCV-cirrhosis: what we know and what is missing.  J Hepatol. 2006;  44 1013-1016
• 68 Velazquez R F, Rodriguez M, Navascues C A et al.. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis.  Hepatology. 2003;  37 520-527
• 69 Ganne-Carrie N, Chastang C, Chapel F et al.. Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in western patients with cirrhosis.  Hepatology. 1996;  23 1112-1118
• 70 Suzuki S, Kondo Y, Hirashima N et al.. Evaluation of loss of heterozygosity before and after interferon therapy in patients with hepatitis C virus infection who developed hepatocellular carcinoma during follow up.  J Gastroenterol Hepatol. 2003;  18 1364-1372
• 71 Roncalli M, Bianchi P, Grimaldi G C et al.. Fractional allelic loss in non-end-stage cirrhosis: correlations with hepatocellular carcinoma development during follow-up.  Hepatology. 2000;  31 846-850
• 72 Kim S, Park Y M. Specific gene expression patterns in liver cirrhosis.  Biochem Biophys Res Commun. 2005;  334 681-688
• 73 Kim J W, Ye Q, Forgues M et al.. Cancer-associated molecular signature in the tissue samples of patients with cirrhosis.  Hepatology. 2004;  39 518-527